BostonGene key facts
- Developer of a biomedical software designed for advanced patient analysis and personalized therapy.
- BostonGene’s last known valuation is $1.5B.
- It has raised $320.0M; the latest was Later Stage VC ($120.0M) in Dec 2024.
- Notable investors include Japan Industrial Partners, Impact Investment Capital, NEC (Japan).
- Status: Privately Held (backing).
Who backs BostonGene
3- ·Watch BostonGene: the Monday email on marks, rounds and moves
BostonGene funding rounds
No funding rounds for BostonGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BostonGene valuation
BostonGene's last known valuation is $1.5 billion. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
BostonGene investors
3 investors are on record for BostonGene, including Japan Industrial Partners, Impact Investment Capital and NEC (Japan).
About BostonGene
Developer of a biomedical software designed for advanced patient analysis and personalized therapy. The company's software offers an artificial intelligence-powered molecular genetic and immune profiling platform to decode cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets, and recommend effective treatments, enabling clinicians to get precise, clinically validated insights that drive precision medicine and advance oncology research.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2015
- Employees
- 300
- Website
- bostongene.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BostonGene’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.